Health & Fitness
Health and Fitness
Health and Fitness
Thu, February 24, 2011Wed, February 23, 2011Tue, February 22, 2011Mon, February 21, 2011Sun, February 20, 2011Fri, February 18, 2011Thu, February 17, 2011Wed, February 16, 2011Tue, February 15, 2011Mon, February 14, 2011Fri, February 11, 2011Thu, February 10, 2011Wed, February 9, 2011Tue, February 8, 2011Vyteris to Present at the Lippert/Heilshorn Life Sciences & Medical Technologies Virtual Conference on February 17
Published in Health and Fitness on Wednesday, February 16th 2011 at 5:05 GMT by Market Wire
FAIR LAWN, N.J.--([ BUSINESS WIRE ])--Vyteris, Inc. (OTCBB: VYTR), an innovator in alternative drug delivery technology, announces that Haro Hartounian, Ph.D., President and Chief Executive Officer of Vyteris, will deliver a corporate presentation as part of the Lippert/Heilshorn & Associates Life Sciences & Medical Technologies On-Line Forum on Thursday, February 17, 2011 at 10:00 a.m. Eastern time.
Dr. Hartounian will provide an overview of the Company and its proprietary smart patch technology, as well as an update on the company's strategic merger with MediSync BioServices, Inc., a consolidator of contract research and site management organizations.
A live webcast of the presentation will be accessible online at the PrecisionIR event site: [ http://www.informedinvestors.com/IIF/IIF_Forum.asp?ForumID=163285 ] as well as on the Companya™s website at [ www.vyteris.com ]. An archived version will be available for 30 days on both sites.
About Vyteris
Vyteris, Inc. is the maker of the first active, ready-to-use drug delivery patch (LidoSite®) to receive marketing clearance from the U.S. Food and Drug Administration. Vyteris' proprietary active transdermal smart patch technology delivers drugs comfortably through the skin using low-level electrical energy (iontophoresis). This smart patch technology is intended to allow precise dosing, giving physicians and patients control in the rate, dosage and pattern of drug delivery that may result in considerable therapeutic, economic, and lifestyle advantages over existing methods of drug administration. Vyteris has successfully delivered a peptide non-invasively using its system, where the Company demonstrated achievement of therapeutic levels of a peptide without using any needles. For more information, please visit [ www.vyteris.com ].
Forward-Looking Statements
This press release includes "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Words such as "expect," "estimate," "project," "anticipate," "intend," "plan," "may," "will," "could," "would," "should," "believes," and similar expressions are intended to identify such forward-looking statements. Forward-looking statements in this press release include, without limitation, statements concerning the potential impact of the new marketing agreement and other matters that involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to differ materially from results expressed or implied by this press release. Such risk factors include, among others, the competitive environment and competitive responses to the new marketing arrangement. The Company has described other important risks and uncertainties under the caption "Risk Factors" in its most recent Annual Report on Form 10-K and in various filings made with the SEC. Actual results may differ materially from those contained in the forward-looking statements in this press release.
